Merck & Co., Inc. (LON:0QAH)

London flag London · Delayed Price · Currency is GBP · Price in USD
85.47
+0.96 (1.13%)
At close: Nov 6, 2025
1.13%
Market Cap162.65B
Revenue (ttm)47.79B
Net Income (ttm)14.16B
Shares Outn/a
EPS (ttm)5.62
PE Ratio11.49
Forward PE9.41
Dividend2.45 (2.87%)
Ex-Dividend DateSep 15, 2025
Volume6,859
Average Volume23,650
Open84.26
Previous Close84.52
Day's Range84.19 - 86.00
52-Week Range70.15 - 105.04
Beta0.32
RSI50.73
Earnings DateOct 30, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]

Sector Healthcare
Founded 1891
Employees 75,000
Stock Exchange London Stock Exchange
Ticker Symbol 0QAH
Full Company Profile

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD Financial Statements

News

There is no news available yet.